Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

about

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.

P2860

Q40100583-F10C8302-4D54-4B2E-8D51-6B796A1DE90A

P2860

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

Item

http://www.wikidata.org/entity/Q40197692

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacogenomic biomarkers as ...... mapping of ClinicalTrials.gov.

@en

type

Item

label

Pharmacogenomic biomarkers as ...... mapping of ClinicalTrials.gov.

@en

prefLabel

Pharmacogenomic biomarkers as ...... mapping of ClinicalTrials.gov.

@en

P1476

Pharmacogenomic biomarkers as ...... mapping of ClinicalTrials.gov

@en

P2093

Jacques Li

http://www.w3.org/2001/XMLSchema#string

Jean-David Zeitoun

http://www.w3.org/2001/XMLSchema#string

Samia Mourah

http://www.w3.org/2001/XMLSchema#string

P2860

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

Genome Medicine in Cancer: What's in a Name?

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Designing transformative clinical trials in the cancer genome era.

Expanded RAS: refining the patient population

P2888

gim.2015.165

P304

796-805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/GIM.2015.165

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287327340

http://www.w3.org/2001/XMLSchema#string

P6179

1039341952

http://www.w3.org/2001/XMLSchema#string

P698

26681315

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

biomarker

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

about

P2860

P2860

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P921